Navigation Links
Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
Date:7/22/2009

r any other infections before or while using ASMANEX. Contact your health care provider immediately if you or your child have been exposed.

Patients who use inhaled steroids, including ASMANEX, for a long time may have an increased risk of decreased bone mass, which can affect bone strength. Patients who are at increased risk of decreased bone mass should be monitored.

Inhaled steroids, including ASMANEX, may cause a reduction in growth velocity when administered to pediatric patients. The long-term effect on final adult height is unknown. Health care providers should closely follow the growth of children and adolescents taking corticosteroids by any route, and reduce each patient's dose to the lowest dose that effectively controls his/her symptoms.

ASMANEX may increase the risk of some eye problems such as cataracts, glaucoma, and increased intraocular pressure. Patients with a change in vision or a history of eye problems should be monitored by their health care provider.

Use ASMANEX as directed by your health care provider, since its ability to work in your lungs depends on regular use. Maximum benefit may take 1 to 2 weeks or longer. If your asthma symptoms do not improve, or get worse, contact your health care provider.

The most common side effects with ASMANEX in patients 4-11 years old include fever, allergic rhinitis, abdominal pain, vomiting, urinary tract infection, and bruise.

The most common side effects with ASMANEX in patients greater than or equal to 12 years old include headache, allergic rhinitis, sore throat, and upper respiratory infection.

Please see additional important product information for ASMANEX TWISTHALER.

You are enc
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.C. , Jan. 23, 2015 For the pharmaceutical ... in dealing with payers. Likewise, the importance of the managed ... will only continue to grow as payer formularies and provider ... therapies. At the same time, managed markets leaders ...
(Date:1/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/5dh22x/urinary_catheters ) ... Market (Indwelling or Foley Catheters, Intermittent Catheters and Male ... Share, Growth, Trends and Forecast 2014 - 2020" ... present, the global market for urinary catheters is experiencing ...
(Date:1/23/2015)...  MedScope ( www.medscope.org ), the leading provider of medical ... Connected World magazine Connected World Award for its ... be used anywhere, anytime. The nomination was made by ... nominating MedScope, Landon Garner , Director of Marketing ...
Breaking Medicine Technology:As Payer Influence Rises, Pharmaceutical Companies work to Optimize the Managed Markets Function 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Urinary Catheters Market (Indwelling or Foley Catheters, Intermittent Catheters and Male External or Condom Catheters) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2
... WEST BEND, Wis., Aug. 8, 2011 Eurofins ... service provider and Spaulding Clinical Research, LLC., US-based, ... Device Manufacturer, announce a joint partnership agreement.  This ... facilitates collaboration on integrated clinical services to engage ...
... Va., Aug. 8, 2011 Science Applications International ... has completed the acquisition of Vitalize Consulting Solutions ... and information technology (IT) services for healthcare enterprises. ... the commercial hospital market that are implementing electronic ...
Cached Medicine Technology:Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research 2SAIC Completes Acquisition of Vitalize Consulting Solutions, Inc. 2
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 The Incredible ... Bodybuilder Ben Pakulski to increase lean muscle by up to ... has caught the attention of HealthyandFitZone.com’s Stan Stevenson, prompting an ... that it is a step-by-step, scientific diet formula that allows ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Autocarinsurancebest.com has released ... purchasing a commercial auto insurance policy . , Auto ... their vehicles. It is no longer necessary to call an ... are now available online on a single website: http://autocarinsurancebest.com/ ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
(Date:1/22/2015)... 2015 Four years since the release of their ... with the marriage of Avasa & Matthew Love – the duo ... scheduled for release through White Swan Records on February 24, 2015. ... a sacred path available to all of us to walk out ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... in Russia, Expanding ... Patients, Cancer Treatment Options, SUNNYVALE, Calif., Nov. 19 ... the field of radiosurgery,announced today that the N. N. Blokhin ... Radiosurgery System. Once,installed, this will be the first CyberKnife System ...
... (NYSE: BSX ) today announced that an ... with a series of product communications,issued by Guidant ... last year. This agreement amends a prior agreement ... unanticipated claims. The amended agreement was reached ...
... rate in subset of patients with ... Anaplastic ... KERX ) today announced that early results of a phase II ... presented in a poster presentation on Saturday, November 17,2007 at the ...
... Medical,Technologies Inc. (the "Company") (Nasdaq: CMED ... develops, manufactures and markets advanced in-,vitro diagnostic ... tumor,therapy systems, today announces the appointment of ... Yuedong Li as member for both audit ...
... 21st century mums are more likely,to turn to the internet ... judged on their parenting skills than in other environments,new research ... that only 2% of mothers felt,judged by their online peers ... other mums at the school gate. The findings mark the,launch ...
... CorVel Corporation,(Nasdaq: CRVL ) today announced ... stock under the stock repurchase program previously approved,by ... the Board had approved a,1,500,000 share expansion to ... has repurchased 862,323 shares, with a remaining 637,677,shares ...
Cached Medicine News:Health News:Leading Russian Cancer Center Acquires CyberKnife(R) System 2Health News:Leading Russian Cancer Center Acquires CyberKnife(R) System 3Health News:Boston Scientific Announces Amended Agreement to Settle Product Lawsuits 2Health News:Boston Scientific Announces Amended Agreement to Settle Product Lawsuits 3Health News:Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology 2Health News:Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology 3Health News:Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology 4Health News:Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology 5Health News:China Medical Technologies Announces Changes in Board of Directors and Appointment of Chief Technology Officer 2Health News:China Medical Technologies Announces Changes in Board of Directors and Appointment of Chief Technology Officer 3Health News:Mums Go Online to Avoid Judgement 2Health News:CorVel Corporation Announces Resumption of Stock Repurchases 2Health News:CorVel Corporation Announces Resumption of Stock Repurchases 3
... classic designs paired with modern, feminine styling. ... materials including ultra-light titanium to 3-D acetate ... almonds and squares. Three-piece mounts and nylon ... wear collection is the perfect combination of ...
... The new Chanel optical collection, ... elegance dear to Mademoiselle's heart, ... to the quilted effect. Combining ... the sparkle of Strass and ...
... Luxury and professionalism. Glamour and style. Creativity ... Luxottica, two market-leading companies, signed a new ... Gabbana brand was formed in 1985 by ... Stefano Gabbana, who blended sensuality with their ...
... includes three collections - Nike Suns, Nike ... active lifestyle consumers the latest vision technology ... sun collections feature Nikes Max Lens technology ... larger vision sweet spot for optimal sport ...
Medicine Products: